Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 141Lung Neoplasms 51Pancreatic Neoplasms 30Non-Squamous Non-Small Cell Lung Cancer 18Neoplasms 15Adenocarcinoma of Lung 14Head and Neck Neoplasms 13Glioblastoma 13Gliosarcoma 12Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Carcinoma, Hepatocellular 9Adenocarcinoma, Bronchiolo-Alveolar 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Squamous Cell 7Carcinoma, Renal Cell 7Astrocytoma 6Oligodendroglioma 5Carcinoma 5Urinary Bladder Neoplasms 4Liver Neoplasms 4Glioma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3

Interventions

trametinib 1dehydroftorafur 1Sorafenib 1Self Expandable Metallic Stents 1Leucovorin 1Gemcitabine 1Fluorouracil 1Erlotinib Hydrochloride 1Drug Therapy 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Klatskin Tumor × Erlotinib Hydrochloride × Clear all
NCT01093222 2015-06-30

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 16 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡